5 471

Cited 61 times in

A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B

Authors
 Hyo-Suk Lee  ;  Young-Hwa Chung  ;  KwanSik Lee  ;  Kwan Soo Byun  ;  Seung Woon Paik  ;  Joon-Yeol Han  ;  Kwon Yoo  ;  Hee-Won Yoo  ;  Jin Heon Lee  ;  Byung Chul Yoo 
Citation
 HEPATOLOGY, Vol.43(5) : 982-988, 2006 
Journal Title
 HEPATOLOGY 
ISSN
 0270-9139 
Issue Date
2006
MeSH
Adult ; Antiviral Agents/therapeutic use* ; Arabinofuranosyluracil/analogs & derivatives* ; Arabinofuranosyluracil/therapeutic use ; Female ; Hepatitis B e Antigens/blood* ; Hepatitis B, Chronic/blood* ; Hepatitis B, Chronic/drug therapy* ; Humans ; Male ; Time Factors
Abstract
Clevudine is a nucleoside analog with an unnatural β-L configuration. In a phase I/II clinical trial, once daily doses ranging from 10 to 200 mg for 28 days were well tolerated, and produced significant antiviral activity. The present study was conducted to assess the degree and durability of the antiviral response to 12 weeks of clevudine treatment, and to investigate its safety and tolerability. A total of 98 patients with HBeAg-positive chronic hepatitis B were randomized to placebo (n = 32), 30-mg clevudine (n = 32), and 50-mg clevudine (n = 34) groups. Patients were followed up after 12 weeks of treatment for a further 24 weeks off-therapy. Median serum hepatitis B virus DNA reductions from baseline at week 12 were 0.20, 4.49, and 4.45 log10 copies/mL in the placebo, 30-mg clevudine, and 50-mg clevudine groups, respectively (P < .0001). Posttreatment antiviral activities were sustained, with 3.32 and 2.99 log10 reductions at week 12 off-therapy and 2.28 and 1.40 log10 reductions at week 24 off-therapies in the 30- and 50-mg clevudine groups, respectively. Median serum alanine aminotransferase (ALT) levels decreased markedly from baseline during clevudine treatment and were maintained below the upper limit of normal throughout the 24 weeks off-therapy in the two clevudine-treated groups. The incidences of adverse events and treatment-emergent grade 3 or 4 laboratory abnormalities were similar for the three groups. In conclusion, clevudine showed potent antiviral activity during therapy and induced a sustained posttreatment antiviral effect for 6 months after a 12-week treatment period, and this was associated with a sustained normalization of ALT levels.
Full Text
http://onlinelibrary.wiley.com/doi/10.1002/hep.21166/abstract
DOI
10.1002/hep.21166
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Kwan Sik(이관식) ORCID logo https://orcid.org/0000-0002-3672-1198
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/110130
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse